Concerns Over the Pace of its Brinsupri’s Launch Hurt Insmed (INSM)

2 months ago 24

Soumya Eswaran

Fri, July 24, 2026 astatine 8:59 AM CDT 3 min read

ClearBridge Investments, a planetary equity manager, precocious published second-quarter 2026 commentary for its "Small Cap Growth Strategy". A transcript of the missive tin beryllium downloaded here. The Russell 2000 Growth Index accrued by 25.6% successful the 2nd quarter, marking its third-best quarterly show successful 2 decades. The rally was fueled by enthusiasm for AI, spot successful biotech, and gains successful high-beta, high-momentum stocks, amid rising retail trading enactment and constrictive enactment successful circumstantial themes. Despite a analyzable macroeconomic backdrop and ongoing debates astir the gait and interaction of AI infrastructure investments, enthusiasm for generational exertion investments remains robust. The Strategy achieved beardown implicit returns of implicit 21% (gross) during the 4th but lagged the Russell 2000 Growth benchmark owed to underperformance successful definite healthcare and fiscal stocks, bundle challenges, and constricted vulnerability to high-beta, high-momentum AI-related stocks. In addition, delight cheque the Strategy's apical 5 holdings to cognize its champion picks successful 2026.

In its Q2 2026 capitalist letter, Clearbridge Small Cap Growth Strategy highlighted Insmed Incorporated (NASDAQ:INSM). Insmed Incorporated (NASDAQ:INSM) is simply a biopharmaceutical institution focusing connected processing therapies for patients with superior and uncommon diseases. On July 23, 2026, Insmed Incorporated (NASDAQ:INSM) closed astatine $107.41 per share, reflecting a marketplace capitalization of $23.28 billion. Insmed Incorporated (NASDAQ:INSM) posted a one-month instrumentality of 3.06%, and its shares gained 2.50% implicit the past 52 weeks.

Clearbridge Small Cap Growth Strategy stated the pursuing regarding Insmed Incorporated (NASDAQ:INSM) successful its Q2 2026 capitalist update:

"In wellness care, weakness was concentrated successful a fewer idiosyncratic holdings, contempt a beardown 4th for biotech. Long-standing biotech holding Insmed Incorporated (NASDAQ:INSM) gave up immoderate of the anterior year's spot driven by concerns astir the gait of cardinal cause Brinsupri's launch. We stay assured successful the meaningful semipermanent highest income imaginable and judge caller weakness has been overly punitive."

Competitive Pressures Prompt Truist to Cut Target connected Insmed (INSM)

Insmed Incorporated (NASDAQ:INSM) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 67 hedge money portfolios held Insmed Incorporated (NASDAQ:INSM) astatine the extremity of the archetypal quarter, compared to 75 successful the erstwhile quarter. While we admit the imaginable of Insmed Incorporated (NASDAQ:INSM) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article